FROM SENSORS TO INSIGHTS: A SCOPING REVIEW OF AI/ML APPLICATIONS IN WEARABLE HEALTH MONITORING FOR DIABETES

Komal Dandge[1], Dr. Manisha Kumawat[2], Dr. Parul Jadhav[3]

[1]Dr Vishwanath Karad MIT World Peace University, PUNE- 411038. Maharashtra
[2]Dr. Vishwanath Karad MIT World Peace University, PUNE- 411038. Maharashtra
[3]Dr. Vishwanath Karad MIT World Peace University, PUNE - 411038. Maharashtra

komal.dandge@gmail.com[1]
manisha.kumawat@mitwpu.edu.in[2]
parul.jadhav@mitwpu.edu.in[3]

ABSTRACT
Advancements in wearable health technologies, combined with artificial intelligence (AI) and machine learning (ML), are revolutionizing how diabetes is monitored and managed. This paper presents a detailed review of cutting-edge AI/ML techniques utilized in wearable systems, with a particular emphasis on noninvasive, real-time blood glucose monitoring methods. The review explores the application of wrist-based photoplethysmography (PPG) signals for estimating glucose levels, along with the integration of IoT-enabled continuous glucose monitoring (CGM) systems. A systematic analysis was performed using databases such as IEEE Xplore, PubMed, Scopus, and Web of Science, selecting studies that demonstrate strong innovation, technical robustness, and clinical importance. The review identifies significant improvements in the precision and efficiency of AI/ML algorithms, as well as progress toward their practical implementation. However, challenges such as data variability, signal interference, and effective sensor fusion remain. The potential for these technologies to support early diagnosis, enable individualized treatment plans, and enhance patient care is substantial. The findings highlight the importance of collaborative, interdisciplinary research to overcome current limitations and bring these innovations into mainstream clinical use.

Keywords-Artificial intelligence, machine learning, wearable health monitoring, diabetes management, continuous glucose monitoring, Internet of Things, predictive analytics, noninvasive devices

I. INTRODUCTION

A. *Background and Rationale*

Diabetes mellitus is a major global health challenge, affecting over 537 million adults worldwide—a number projected to exceed 600 million by 2030 [1]. It is a leading cause of morbidity and premature mortality due to complications like cardiovascular disease, neuropathy, and retinopathy [2–4], with a substantial economic burden from healthcare costs and lost productivity.

Advancements in wearable technologies have transformed diabetes management. Devices such as continuous glucose monitors (CGMs) like the Dexcom G6 and FreeStyle Libre now enable real-time glucose tracking [5], supported by innovations in microelectronics and wireless data transmission [6]. Additionally, modern wearables capture diverse physiological signals, allowing for more comprehensive health monitoring.

Artificial intelligence (AI) and machine learning (ML) have further revolutionized this domain. Algorithms such as neural networks and support vector machines are increasingly used to interpret sensor data, predict glucose fluctuations, and detect hypoglycemic events [7,8]. However, challenges like data sparsity, sensor variability, and real-time processing limitations remain barriers to clinical integration [9].

This scoping review aims to map the current landscape of AI/ML applications in wearable diabetes monitoring, identify research trends and gaps, and propose future directions for clinical translation.

B. *Research Problem and Gap*

Despite rapid AI/ML advancements, their integration into wearable diabetes monitoring systems remains limited. Existing models often lack clinical robustness and real-world validation.

To address this, we adopted a rigorous review protocol combining narrative and thematic synthesis, supported by visual tools (e.g., tables, charts, network maps) and NVivo-assisted coding, to ensure transparency and analytical depth in identifying key challenges and future opportunities.

This protocol serves as a structured framework, ensuring methodological rigor, reproducibility, and transparency in the review process.

II. METHOD

A. *Eligibility Criteria*

Eligibility criteria were developed using the Population–Concept–Context (PCC) framework to ensure a rigorous and relevant selection of studies exploring AI/ML applications in wearable health monitoring for diabetes.

1) *Inclusion Criteria:*

a) *Study Types:*

- *Primary Research*: Experimental (RCTs, cohort, case-control), observational (cross-sectional, pilot), and proof-of-concept studies with AI/ML integration in wearable monitoring.
- *Secondary Research*: Systematic reviews, meta-analyses, and scoping reviews.
- *Conference Papers*: Peer-reviewed contributions from reputable venues (e.g., IEEE, ACM, NeurIPS, AAAI, MEDINFO).
- *Grey Literature*: Reports from agencies, professional bodies, and industry (e.g., WHO, FDA).
- *Population*: Human subjects with Type 1 or Type 2 diabetes, or at high risk. Studies with healthy controls were included if relevant to model differentiation.
- *Interventions*: Wearable sensors integrated with AI/ML for:
  - Glucose prediction andhypoglycaemia/hyperglycaemia detection
  - Insulin dosage support
  - Anomaly detection
  - Risk stratification and trend analysis
    Devices include CGMs (Dexcom, Libre), smartwatches (Apple Watch, Fitbit), biosensors, and multi-modal platforms.
- *Outcomes* (at least one):
  - AI/ML performance (accuracy, AUC, sensitivity, etc.)
  - Clinical utility
  - Data quality handling
  - Implementation challenges
  - Future research recommendations
- *PublicationCharacteristics*: English-language studies from the last 10 years.

2) *Exclusion Criteria:*

- Studies unrelated to diabetes-specific wearables or lacking AI/ML integration.
- Work focusing solely on hardware development without analytical models.
- Non-peer-reviewed content (e.g., blogs, opinion pieces).
- Studies lacking methodological transparency or duplicating prior work.

3) ***Rationale**:* These criteria ensure the inclusion of high-quality, relevant studies with methodological rigor. Quality assessment tools include Cochrane RoB2 (RCTs), ROBINS-I (observational studies), and AMSTAR 2 (reviews).

B. *Information Sources*

A comprehensive literature search was conducted across major databases and grey literature to capture both peer-reviewed and emerging research.

1) *Databases:*

- *IEEE Xplore*: Engineering and wearable systems.
- *PubMed*: Biomedical and clinical literature.
- *Scopus* and *Web of Science*: Multidisciplinary coverage of AI/ML and healthcare research.

2) *Grey Literature:*

- *Google Scholar* and *Preprint Servers* (arXiv, bioRxiv, medRxiv) for early-stage studies.
- Reports from organizations (e.g., WHO, ADA, FDA) for regulatory and deployment perspectives.

3) *Conferences:Peer-reviewed papers from BHI, AIME, NeurIPS, AAAI, MEDINFO, and related venues.*

4) *Citation Chaining:*Reference lists and citations from key studies were manually screened to identify additional relevant literature.

C. *Search Strategy*

A structured, reproducible search strategy was developed using Boolean logic, MeSH terms (PubMed), and database-specific keywords.

1) *Key Concepts:*

a) Population: “Diabetes,” “Type 1/2 Diabetes,” “Blood Glucose Monitoring”
b) Intervention: “Wearable Sensors,” “CGM,” “Smartwatch,” “Biosensors”
c) AI/ML: “Artificial Intelligence,” “Machine Learning,” “Deep Learning,” “Predictive Analytics”

2) ***Sample Search String (PubMed)****:*

("Diabetes Mellitus" OR "Type 1 Diabetes" OR "Type 2 Diabetes") AND ("Wearable Sensors" OR "CGM" OR "Smartwatch") AND ("Artificial Intelligence" OR "Machine Learning")

Search strategies were tailored per database. Pilot searches were conducted and refined iteratively for precision and recall. Two reviewers independently conducted and documented the search.

D. *Study Selection*

A two-stage screening approach ensured unbiased and systematic inclusion.

1) ***Stage 1** – Title and Abstract Screening:*Two reviewers independently screened records based on eligibility criteria. Disagreements were resolved through discussion or adjudicated by a third reviewer.

2) ***Stage 2** – Full-Text Review:*Full texts of potentially eligible studies were reviewed against inclusion/exclusion criteria. Reasons for exclusion were documented. A PRISMA flowchart summarizes the selection process.

E. *Data Extraction and Charting*

A standardized data extraction form was used to collect information systematically. A pilot test ensured consistency and completeness.

1) *Data Fields:*

- Metadata: Authors, year, journal, DOI
- Study Characteristics: Design, sample,demographics
- Wearable Technology: Sensor types, placement, frequency
- AI/ML Models: Model types, features, datasets, preprocessing
- Outcomes: Accuracy, AUC, sensitivity, interpretability
- Limitations: Data quality, generalizability, biases

2) *Tools:*

- *Excel*: For structured data logging

- *NVivo*: For qualitative coding and theme identification
- Dual review ensured accuracy, with a third reviewer resolving discrepancies.

F. Quality and Bias Assessment

Though not mandatory for scoping reviews, an adapted quality assessment was conducted to evaluate study robustness.

1) Quality Indicators:

- Study design rigor
- AI/ML model transparency and reproducibility
- Data integrity
- Generalizability
- Bias risks (e.g., sampling bias, overfitting, data imbalance)

An appraisal table documented result. A narrative summary highlights common strengths and limitations across studies.

G. Data Synthesis and Analysis

A multi-method approach combined qualitative and quantitative techniques to synthesize findings.

1) ***Narrative Synthesis****:*Studies were grouped by:

- AI/ML methodology (e.g., supervised learning, deep learning)
- Wearable types (CGMs, smartwatches, biosensors)
- Study design (RCTs, observational, real-world)

2) ***Thematic Analysis****:*NVivo was used to identify recurring themes across studies, focusing on:

- Model performance (accuracy, AUC, interpretability)
- Clinical utility and patient engagement
- Deployment barriers (data quality, regulatory issues)
- **Visualization**:
- *PRISMA Diagram*: Study inclusion process
- *Tables*: Summary of AI/ML methods, devices, outcomes
- *Charts*: Model performance (accuracy, sensitivity)
- *Network Diagrams*: Relationships among technologies, models, and clinical use cases

3) ***Integration****:*Findings were synthesized using a matrix framework linking narrative insights, thematic categories, and visual patterns to identify gaps and guide future research.

III. RESULT

A. Overview of Included Studies

This section summarizes the 87 studies included in the scoping review, categorized by study design, research objectives, sample sizes, and methodological focus areas.

1) *Study Selection Overview:* A total of **87 studies** were analyzed. The PRISMA flow diagram (Figure. 1) outlines the inclusion/exclusion process.



Figure 1: PRISMA Flow Diagram

2) *Study Design Classification:* The studies were categorized into four main designs, summarized in Table I with the help of Figure2.

TABLE I: CLASSIFICATION OF STUDIES BASED ON RESEARCH DESIGN

Study Design	**Number ofStudies (N)**	**Proportion (%)**
Experimental Studies	59	67.8%
Observational Studies	8	9.2%
Review Articles	20	23.0%
Comparative &Benchmarking Studies	5	5.7%
Total	**87**	**100%**



Figure 2: Pie Chart of Study Design Distribution

3) *Study Design Summaries:*

Study design summary is included in Table II and Visual Summary of Sample Sizes and Demographic Trends represented in Figure 3.

TABLE II: SUMMARY OF INCLUDED STUDIES CATEGORIZED BY RESEARCH DESIGN

Type	Focus	Representative Studies / Key Contributions
Experimental (n=59)	Model development, wearable integration, predictive analytics	Non-invasive CGM [69, 80], PPG-based prediction [81], Lab-data models [82, 89]
Observational (n=8)	Pattern analysis in real-world data	ECG-based detection [86], Stratification [78]
Review Articles (n=20)	Syntheses and surveys	Reviews on non-invasive monitoring [53, 54, 58–60, 65–67, 88], Wearable tech reviews [71–73, 76]
Comparative/Benchmarking (n=5)	Cross-model evaluations	Classical vs deep learningcomparisons, datasetrobustness [multiplestudies]

4) *Sample Size & Demographics Summary*

Studies ranged from small-scale pilot studies to large cross-sectional datasets. A summarized breakdown is presented in Table III.

TABLE III: SAMPLE SIZES AND POPULATION SCOPE ACROSS STUDIES

Category	Details	Examples
Small-scale /In-silico	≤12 participants	OhioT1DM (12) [1,6]; Single-patient study [49]
Moderate-scale cohorts	20–500participants	PPG study (290) [24]; IoMT study (283) [75]
Large	>1,000participants	Cross-sectional

datasets /Combined sources	or aggregated datasets	study (10,794) [74]; Combined datasets [27, 34]
Specialized cohorts	Demographic-specific	Pinggu cohort [78]; Sindhi ECG cohort (1,262) [86]



Figure 3: Visual Summary of Sample Sizes and Demographic Trends

5) Research Themes and Core Objectives

Key research questions were grouped under five primary themes. Table IV highlights representative examples.

TABLE IV: AI/ML RESEARCH THEMES IN DIABETES MONITORING AND PREDICTION

Theme	**Focus Areas**	**Representative Studies**
Glucose Prediction & Control	Personalization, multitask learning, insulin dosing, reinforcement learning	[6, 9, 17, 25, 33, 36, 42]
Non-Invasive Wearable Monitoring	PPG, NIRS, e-textiles, sweat sensors	[8, 24, 40, 57, 70, 80, 85]
Data Integration & Predictive Analytics	Multi-source data, EHRs, missing value handling	[27, 29, 34, 39, 46]
IoT & Web Platforms	Real-time remote monitoring and interactive platforms	[7, 28, 34, 45, 63]

Comprehensive Reviews	Trends, gaps, wearable applications, new sensor technologies	[54, 58, 59, 65, 66, 71–73]

6) Noteworthy Technical Innovations

- Use of **CRNNs and ensemble deep learning** for predictive modeling [9, 16]
- **ECG and PPG signal-based detection** [81, 86, 87]
- Integration of **TCM features** with ML [61]
- Development of **user-friendly nomograms and IoT-based CGM** systems [74, 75, 80]

B. Wearable Sensor Technologies for Diabetes Monitoring

Wearable sensor technologies, particularly Continuous Glucose Monitors (CGMs), smartwatches, and non-invasive biosensors, are transforming diabetes management through real-time and continuous monitoring. This section categorizes key technologies and summarizes study applications.

1) Continuous Glucose Monitors (CGMs): CGMs provide dynamic glucose tracking using subcutaneous sensors and are widely adopted in clinical and research settings Table V gives idea aboutOverview of Continuous Glucose Monitoring Devices and Their Usage in Reviewed Studies.

TABLE V: OVERVIEW OF CONTINUOUS GLUCOSE MONITORING DEVICES AND THEIR USAGE IN REVIEWED STUDIES

Device	**Studies Referenced**	**Notes**
Medtronic Enlite	[1], [4], [13], [28], [52]	Often paired with insulin pumps
Dexcom	[9], [50], [64]	Widely used in IoMT-integrated systems
FreeStyle Libre	[9]	Common in home and clinical settings
Microneedle & Flexible CGMs	[73]	Enhance comfort and accuracy

*2) Smartwatches, Fitness Trackers, & Smartphone Systems:*These wearables capture additional biosignals (e.g., heart rate, PPG, ECG) and are integrated with mobile apps for continuous monitoring Table VI gives idea about it.

TABLE VI: SENSOR-INTEGRATED WEARABLE DEVICES AND PLATFORMS UTILIZED IN REVIEWED STUDIES

Device/Platform	**Sensors**	**Studies**
Empatica E4	PPG	[85]
Zephyr Bioharness 3	ECG, Respiratory	[79]
Smartwatch + Smartphone	PPG	[8]
Mobile IoT Glucose Monitors	Glucose, Cortisol	[64], [80]

3) *Summary Table: Wearables in Reviewed Studies*

Table VII gives summary of wearable sensor usage.

TABLE VII: SUMMARY OF WEARABLE SENSOR USAGE

Study	Wearable Sensor(s) Used	Devices	Reference
Study1	CGM, Fitness Tracker	Medtronic EnliteCGM, Activity Bands	[1]
Study2	CGM	Medtronic EnliteCGM	[4]
Study 3	CGM	Dexcom, FreeStyle Libre	[9]
Study 4	CGM	Medtronic Enlite CGM	[28]
Study 5	CGM	Dexcom	[50]
Study 6	CGM	Medtronic Enlite CGM	[52]
Study 7	PPG, ECG Sensors	Empatica E4, Other Wearables	[85]
Study 8	ECG, Other Sensors	Zephyr Bioharness 3	[79]
Study 9	Smartphone-Based Systems	Various Smartwatches	[8]
Study 10	CGM, IoT	Dexcom,IoT-Enabled Sensors	[64]

4) Noninvasive Biosensors: Optical, PPG, and Electrochemical

a) Optical & PPG-Based Sensors

- **PPG**: Blood volume fluctuation monitoring [22]
- **NIR-PPG**: Enhanced glucose detection using near-infrared light [23]
- **IPS**: Infrared Pulsed Sensing for glucose tracking [24]

b) Custom Optical Platforms

- **Custom Sensors**: Target glucose molecules directly [26]
- **Vis-NIR Systems**: Use broad light spectra [31]
- **Fiber Laser Devices**: Highly sensitive to glucose scattering [60]

c) Alternative Biofluids

- **Sweat/Tear Glucose Sensors**: Non-skin biofluid sensing [72]
- **IoMT Biofluid Sensors**: Wearables measuring glucose from skin or sweat [75]

5) Advanced Biosensor Systems and Integration

Table VIII gives Examples of Multi Modal and Hybrid Sensor Systems in Wearable Health Monitoring.

TABLE VIII: EXAMPLES OF MULTI-MODAL AND HYBRID SENSOR SYSTEMS IN WEARABLE HEALTH MONITORING

Sensor Type / System	**Example Use**	**Reference**
Dual-Wavelength PPG	Red + IR light for glucose accuracy	[81]
Optical + Electrochemical	Multi-modal systems (e.g., VOC-analyzer)	[88], [40]
ECG + PPG Combined Wearables	Cardiovascular and glucose monitoring	[49]
Multi-Modal Textile Wearables	Integrated into clothing for comfort	[59], [66]

6) Challenges & Clinical Implementation

a) Challenges:

- Inconsistent data quality, timestamps, and calibration [77], [82]
- Integration with clinical infrastructure
- Validation across populations
- Clinical Impact:
- Better insulin dosing
- Early hypoglycaemia/hyperglycaemia alerts
- Personalized monitoring and feedback loops [78], [83]

C. Overview of AI/ML Models in Wearable Diabetes Monitoring

Advancements in wearable sensors and AI/ML techniques have driven significant progress in noninvasive diabetes monitoring. Across the reviewed studies, models are primarily categorized into supervised learning, reinforcement learning, and IoT-integrated systems. The objective applications include glucose prediction, risk assessment, hypoglycemia detection, and insulin dosing. Table IX provides a high-level summary.

TABLE IX: OVERVIEW OF AI/ML MODELS USED IN WEARABLE DIABETES MONITORING

Model Type	**Algorithms**	**Target Outcome**	**Data Sources**	**Key Studies**
Supervised Learning	SVM, RF, XGBoost, CNN, LSTM	BG Prediction, Risk Detection	PPG, ECG, NIR, Accelerometers	[1], [9], [24], [81]
Deep Learning	CNN, RNN, GRU, Transformer	Hypoglycemia Warning, Forecast	PPG, Optical, ECG	[4], [14], [28], [89]
Ensemble/Hybrid	Stack-ANN, DCC-Net	Classification, Progression	Multi-modal (PPG + ECG + Meta)	[24], [29], [86]
Reinforcement Learning	SAC + PID + RFR + DAN	Insulin Dosing, BG Optimization	Real-time CGM, IoT	[33], [54]
IoT-Based Systems	Real-time CGM + ML backend	Continuous Monitoring	Cloud-based, Sensor Fusion	[80], [88]

1) Comparative Analysis of Algorithms and Study Focus

The following Table X presents a breakdown of representative studies by algorithm, diabetes type, application domain, and performance highlights.

TABLE X: COMPARATIVE SUMMARY OF STUDIES

Study	**Algorithm(s)**	**Application Focus**	**Diabetes Type**	**Accuracy / Key Metric**
[9]	CRNN (CNN + LSTM)	Glucose Prediction	T1D & T2D	RMSE = 9.38 mg/dL
[14]	GRU + Evidential	Hypoglycemia Forecast	T1D	Sensitivity = 92%
[28]	Transformer (GPFormer)	Multi-horizon Prediction	T1D	30-min Horizon Forecast
[29]	Stack-ANN (Ensemble)	Classification	All	Acc = 99.51%, 98.81%, 98.45%
[33]	SAC + RFR + PID	Adaptive Insulin Control	T1D	RL Policy Optimization
[81]	XGBoost	PPG Signal Classification	T2D	Acc = 96%, AUC = 90%
[86]	XGBoost	ECG Classification	Pre-T2D	Acc = 92%, Precision = 93.2%
[89]	ResNet18	Pulse Wave Image Analysis	T2D	F1 = 92.31%, Acc = 92%

2) Performance Metrics and Evaluation

Across studies, performance is evaluated using standard classification and regression metrics shown in Table XI and Heatmap performance Matrices is shown in Figure 4.These include:

- **Accuracy**: Ranges from 81% to 99%, depending on data modality and task complexity.
- **Regression Metrics**: RMSE, MAE, and MARD are used for continuous glucose prediction.
- **Diagnostic Measures**: AUC-ROC, sensitivity, specificity, and F1-score are common for classification.

Table XI: Performance Metrics Across Selected Models

Study	**Accuracy (%)**	**RMSE**	**MARD (%)**	**Sensitivity**	**AUC-ROC**	**F1-score**
[24]	92.0	—	—	—	—	—
[29]	98.45–99.51	—	—	—	—	—
[81]	96.0	—	—	92.0	90.0	—
[87]	64.5	—	—	56.3	70.5	58.8
[89]	92.0	—	—	91.4	—	92.3

Note: Some studies did not report all metrics. A standard reporting structure is recommended across future work.



Figure 4. Heatmap of Performace Metrics

3) *Trends and Future Perspectives*

- **Personalization**: Many models increasingly focus on adapting to individual differences in physiology, activity levels, and demographics ([1], [86], [87]).
- **Multi-modal Integration**: Fusion of sensor data (e.g., PPG + ECG + motion) enhances model robustness ([69], [88]).
- **Real-Time Analytics**: Some models are embedded into IoT platforms for edge processing and immediate feedback ([80], [54]).
- **Underexplored Areas**: Few studies address federated learning, on-device privacy, and clinical trials at scale.

4) *Summary*

Supervised learning dominates the literature on noninvasive diabetes monitoring using wearable technology. Deep learning models such as LSTM, CNNs, and hybrid ensembles demonstrate high accuracy in prediction tasks. Reinforcement learning, though less explored, shows strong potential for adaptive insulin regulation. Despite promising results, inconsistency in performance metric reporting and the lack of real-world validation remain key gaps.

a) Future work should prioritize:

- Standardized reporting of metrics (accuracy, sensitivity, AUC).
- Broader inclusion of multi-modal and demographic data.
- Deployment of interpretable and clinically validated models in wearable systems.

D. Integration of AI/ML with Wearable Devices

The integration of AI/ML with wearable technology has revolutionized diabetes care, enabling real-time, non-invasive, and personalized monitoring. This section outlines the key modalities, system architectures, and challenges involved in implementing such systems.

1) Real-Time AI Integration and Sensor Modalities

AI/ML models are increasingly embedded in wearable systems—such as CGMs, PPG-based smartwatches, optical sensors, and EM/environmental sensors—to support real-time blood glucose prediction and management.

a) Key approaches include:

- **CGM + AI**: Used for immediate blood glucose level (BGL) prediction and decision support [69][70].
- **PPG Sensors**: Applied for real-time BGL estimation in non-invasive, low-cost settings [8][22][63][69][75][87].
- **Optical/Environmental Sensors**: Deployed in tear analysis, sweat-based sensing, and tongue image processing [41][57][60][61][62].
- **Multimodal Inputs**: Some platforms incorporate insulin dosage, dietary intake, and physiological data for enhanced prediction accuracy [73][76].

2) Advanced Computational Strategies: To improve accuracy and adaptability:

- Hierarchical Feature Fusion and cross-layer architectures refine sensor signal interpretation [22].
- Reinforcement Learning (e.g., SAC-based models) adapt to physiological changes in real-time without requiring prior training data [33].
  - **Automated insulin adjustment systems** integrate real-time inputs from CGMs, insulin logs, and food intake for decision-making [71][73].

Some studies favor low-complexity, **shapelet-based machine learning models** to enable real-time prediabetes or diabetes prediction without heavy computational overhead [81][85].

3) Embedded AI and Edge Computing: AI algorithms are deployed across various embedded platforms

- **Raspberry Pi and SoC devices**: Allow local real-time prediction [14][24].
- **Smartphone-based apps**: Provide user-friendly interfaces for diabetes monitoring [48][55][57].
- **Cloud-Edge Hybrid Systems**: Adapt computation load depending on bandwidth and latency constraints [75].

This flexibility enables AI models to function even under limited processing and connectivity environments.

4) Beyond Traditional Wearables: In addition to conventional sensors

- **Tear-based image analysis** on smartphones supports glucose screening [62].
- **IoT-integrated systems** extend wearable capabilities through continuous connectivity, though some lack explicit AI integration [80].
- ECG and sweat-sensing systems represent promising non-invasive extensions to diabetes diagnostics [57][86].

5) Integration Challenges: Despite promising advances, several technical and practical barriers limit widespread adoption shown in Table XII and Key Integration Features are shown in Table XIII.

TABLE XII: KEY TECHNICAL CHALLENGES IN WEARABLE SENSOR-BASED HEALTH MONITORING AND ASSOCIATED STUDIES

Challenge	**Description**	**Key Studies**
Signal Integrity	Motion artifacts in PPG/ECG data; noisy CGM outputs	[22][69][87]
Computational Load	Complex models (CNN, RNN) are resource-intensive for wearables	[70][71][75][76][86][89]
Battery and Energy Use	Continuous sensing drains battery quickly	[72][73][88]
Calibration and Adaptability	Systems must adjust to inter-subject variability and device errors	[33][70][75][87]
Sensor-Specific Constraints	e.g., sweat sensor selectivity, ECG signal variability	[56][57][80][85]



Figure 5Illustrates a heatmap mapping these challenges to their clinical impact.

6) Clinical Benefits and Impact: AI-powered wearables offer significant clinical promise shown in Figure 5.

- **Real-Time Interventions**: Early warnings for hypoglycemia and hyperglycemia support proactive management [70][73][76].
- **Personalized Treatment**: Integration of diet, activity, and insulin profiles enables individualized care plans [71][73].
- **Enhanced Patient Compliance**: Non-invasive approaches reduce discomfort and promote long-term adherence [81][86][87].
- **Public Health Reach**: Smartwatch-based risk alerts and ECG-based prediabetes tools can aid early diagnosis in low-resource settings [85][86].

Remote monitoring via **IoMT platforms** facilitates clinician intervention, improving both individual outcomes and system-wide care delivery [66][67].

TABLE XIII: SUMMARIZING KEY INTEGRATION FEATURES

Aspect	**Key Features**	**References**
Real-Time AI Integration	Continuous data capture; immediate predictions; personalized treatment	[11][17][38][50][51][70]
Embedded & Edge Processing	Deployment on SoC, Raspberry Pi, smartphones; flexible processing	[14][24][48][55][57]
Integration Beyond Traditional Wearables	IoT-enabled systems; smartphone image processing for tear-based monitoring	[80][62]
Additional Feature Extraction	Shapelet-based analysis; traditional ML for non-invasive predictions	[81][85][86][89]
Challenges in Integration	Data quality issues, computational power, energy consumption, calibration	[22][69][70][71][56][75][76][86][80]
Clinical Impact	Enhanced monitoring; personalized treatment; improved patient compliance	[70][72][73][75][54][63][76][71][81][87][86][66][67]

E. *Limitations and Biases*

The reviewed literature reveals a wide array of limitations and biases affecting the design, performance, and clinical utility of AI/ML models that use sensor data for diabetes monitoring and prediction. These challenges arise from issues such as limited data, algorithmic constraints, sensor inaccuracies, and sample biases, all of which hinder model generalizability and real-world applicability.

1) *Data and Model Limitations*

a) ***Overfitting and Generalization:*** Many studies report insufficient training data, leading to overfitting and reduced model generalizability [1][4][6][36]. Some models are based on single-patient or demographically homogeneous datasets, limiting their broader applicability [53][55].

b) ***Model Complexity:*** The dynamic nature of glucose regulation and the challenge of accurately estimating carbohydrate intake introduce further complexity for predictive models [54].

c) ***Small Sample Sizes:*** Limited sample sizes and lack of multicentre validation are recurring limitations, reducing the robustness and reliability of model evaluations [78][79].

2) Data Quality, Missingness, and Preprocessing

a) ***Sensor Noise and Missing Data:***Wearable sensor datasets often include noise, missing values, and unpredictable fluctuations [9][45][46]. These compromise the reliability of model training and validation.

b) ***Imprecision in Health Records:***Errors in CGM measurements and incomplete EHRs hinder accurate modeling [68][82][85].

c) ***Need for Data Diversity:***A recurring theme is the lack of large-scale, diverse datasets needed to enhance the generalizability of AI models [89].

3) Algorithmic Constraints

a) ***Computational Demands:***Advanced AI techniques like reinforcement learning require extensive training episodes and often rely on simplified physiological assumptions [33][37].

b) ***Model Rigidity:***Certain approaches demand constant adjustment due to the complexity of patient-specific health conditions, making real-time clinical deployment difficult [54].

4) Device and Environmental Constraints

a) ***Controlled vs. Real-World Settings:***Many studies rely on controlled environments that do not reflect real-life variability, undermining external validity [22][40][56].

b) ***Wearable Limitations:***Device-related challenges include the need for energy efficiency, privacy concerns, and data annotation difficulties in health sensor networks [28][86].

5) Sensor and Signal Processing Limitations

a) ***Accuracy and Calibration:***Numerous studies highlight concerns with sensor accuracy, sensitivity, and the need for frequent calibration—particularly in noninvasive modalities [8][25][32][57][72].

b) ***Signal Processing Challenges:***Noise, motion artifacts, and synchronization issues (e.g., with image-based or PPG signals) complicate signal interpretation [18][31][42][87].

c) ***Use-Case Specificity:***Some studies address specialized scenarios (e.g., pregnancy), where validation across physiological conditions becomes essential [41][50][60].

6) Biases in Data Collection and Evaluation

a) ***Sample Representativeness:***Studies often rely on non-representative or uni-regional samples (e.g., single ethnic group or demographic), limiting external validity [22][55][78].

b) ***Controlled Conditions:***Bias may emerge from lab-based (in vitro) setups that overlook real-world physiological variability (in vivo) [40][41].

c) ***Algorithmic and Structural Biases:***Implicit biases stem from model assumptions, use of specific sensor types, or variations across device manufacturers [33][88].

d) ***Lack of Cross-validation Standards:***Some models risk performance inflation due to improper data separation during training/testing, though others mitigate this through cross-validation [87].

7) ***Summary:***Limitations across data quality, algorithm design, environmental constraints, and demographic representation significantly impact the robustness and generalizability of AI/ML systems for diabetes management. Overcoming these challenges will require advancements in sensor design, diverse dataset collection, robust preprocessing techniques, and multicentric study validation.

F. Future Research Directions

To translate AI/ML-integrated wearable health monitoring systems into routine clinical use for diabetes management, future research mentioned in Table XIVmust address current limitations while advancing sensor technology, model adaptability, and personalized care pathways.

1) Enhancing AI/ML Model Capabilities

a) ***Model Interpretability and Robustness:***Current models often act as "black boxes." Future approaches should enhance explainability using techniques like attention mechanisms, relevance propagation, or rule extraction [12][16]. Robustness must be improved through adversarial training and ensemble methods to accommodate noisy and heterogeneous data.

b) ***Multi-Modal Data Fusion:***Combining physiological (e.g., glucose levels), behavioral, and contextual data streams using advanced fusion techniques (e.g., multi-view learning) can enhance predictive performance [2][10].

c) ***Adaptive Learning Techniques:***Strategies such as federated, transfer, or online learning are essential for updating models in real time as new patient data becomes available, ensuring sustained model accuracy [13][24].

d) ***Edge–Cloud Integration:***Hybrid frameworks integrating cloud computing with edge processing will reduce latency, improve scalability, and enhance data privacy in real-time diabetes monitoring applications.

2) Advancing Wearable Sensor Technologies

a) ***Noninvasive Sensor Innovation:***Emphasis should be placed on developing low-power, stable, and highly sensitive noninvasive sensors through innovations in materials and optical sensing [44].

b) ***Holistic Health Monitoring:***Expanding wearable systems to include biosensors for biomarkers like lactate, cortisol, or inflammation could support early detection of comorbid conditions [44].

c) ***Scalability and Interoperability:***Future research must develop standards for sensor calibration, data transmission, and security (e.g., blockchain, encryption) to support secure and scalable health sensor networks.

3) Personalization and Clinical Integration

a) ***Individualized Thresholds and Protocols:***Personalized algorithms must account for patient-specific parameters such as age, comorbidities, and lifestyle, moving away from generalized targets [2][16].

b) ***Proactive Intervention Models:***Systems should support early detection of glycemic events via real-time monitoring and tailored feedback, enabling a shift from reactive to preventive care [24].

c) ***EHR and CDSS Integration:***Future platforms should facilitate seamless, secure integration with Electronic Health Records and Clinical Decision Support Systems to support clinician decision-making.

d) ***Data Governance and Ethics:***Research must also address concerns around data ownership, informed consent, and algorithmic transparency, ensuring ethical deployment of AI in healthcare.

TABLE XIV: VISUAL SUMMARY OF FUTURE FOCUS AREAS

Research Focus	**Key Objectives**
AI/ML Models	Interpretability, robustness, data fusion, adaptive learning, real-time processing
Sensor Technologies	Next-gen noninvasive designs, biosensor integration, interoperability, security
Personalized Care Pathways	Individual thresholds, EHR integration, proactive interventions, ethical frameworks

IV. DISCUSSION

This section provides a critical examination of the integration of artificial intelligence (AI) and machine learning (ML) with wearable technologies for diabetes monitoring. It offers a synthesis of the reviewed literature, compares findings with previous studies, identifies current research gaps, and explores the ethical, regulatory, and practical challenges associated with these technologies. The discussion concludes with an assessment of the strengths and limitations of this review and outlines directions for future research.

1) *Interpretation of Findings:* Our systematic analysis reveals a complex and rapidly evolving landscape wherein AI/ML algorithms are increasingly deployed alongside wearable sensors to enhance diabetes management. These findings are organized into three primary domains: study design characteristics, technological integration, and clinical implications.

a) ***Study Design Characteristics:*** The included studies exhibit considerable methodological heterogeneity, spanning experimental trials, observational studies, review articles, and benchmarking analyses. Experimental studies represent approximately 67.8% of the corpus, with a strong emphasis on developing and validating AI/ML-driven models for non-invasive glucose prediction. While these studies often achieve high internal validity, their external applicability is limited due to variability in population demographics, sensor types, and clinical settings. This diversity, although methodologically enriching, presents challenges for synthesizing findings into broadly generalizable conclusions.

b) ***Integration of AI/ML with Wearable Sensors:*** *T*he integration of AI/ML with wearable devices is primarily focused on advancing predictive modeling and real-time data analysis. Across the literature, we observe a strong trend toward employing deep learning and ensemble methods to process multi-modal sensor data, includingphotoplethysmography (PPG), accelerometry, and electrochemical biosensors. A structured synthesis matrix developed during the review highlights recurring patterns in data acquisition, algorithmic frameworks, and deployment strategies. These models aim to enhance the sensitivity and specificity of glucose monitoring systems, thus supporting dynamic, patient-centric clinical decision-making.

c) ***Clinical Implications:*** AI/ML-enhanced wearables demonstrate substantial potential to transform diabetes care by facilitating continuous monitoring, early detection of glycemic fluctuations, and personalized intervention strategies. By enabling real-time insights, these technologies may empower clinicians and patients alike. However, barriers such as high development and deployment costs, fragmented healthcare IT ecosystems, and lack of standardized clinical validation protocols continue to impede widespread clinical adoption.

2) *Comparison with Existing Literature*

a) ***Alignment with Previous Reviews:*** Earlier reviews have similarly recognized the promise of AI/ML in revolutionizing diabetes management, particularly with respect to personalization of care and predictive analytics. Methodologically, our review aligns with prior systematic and scoping reviews but expands upon them by incorporating a broader range of study designs and technological modalities, including recent innovations in non-invasive sensor technologies.

b) ***Divergence in Emphasis and Approach:*** Unlike prior literature, our review places distinct emphasis on algorithmic innovation and real-world applicability, particularly in the context of sensor integration and model adaptability. The inclusion of a synthesis matrix enables a nuanced cross-study comparison, capturing both best practices and divergences in implementation across varied healthcare settings. This approach offers a more granular understanding of how AI/ML applications are operationalized in practice.

c) ***Multidisciplinary Integration:*** Our interdisciplinary perspective—drawing from clinical medicine, computer science, and biomedical engineering—strengthens the analytical framework and provides a holistic view of the ecosystem. This integration is vital for understanding not only the technological advancements but also the contextual factors influencing deployment, including workflow integration, clinical acceptance, and patient engagement.

3) *Research Gaps and Future Directions:* Despite notable advancements, several critical gaps persist in the literature,

a) ***Real-Time Integration Challenges:*** A key limitation is the difficulty of achieving reliable real-time predictive analytics in dynamic, real-world environments. Factors such as sensor noise, data variability, and the need for continuous model recalibration pose significant obstacles. The lack of uniform data annotation protocols and validation benchmarks further limits cross-study comparability.

b) ***Directions for Future Research****:* Future research should prioritize pilot studies in real-world clinical environments that assess the operational feasibility and clinical utility of AI/ML-integrated wearables. Rigorous experimental designs combined with longitudinal data collection will be crucial. Moreover, fostering collaborations among data scientists, engineers, clinicians, and ethicists will facilitate the development of holistic solutions that are technically sound, clinically relevant, and ethically robust.

c) ***Emerging Technological Innovations****:* Technologies such as edge computing, federated learning, advanced Internet of Things (IoT) architectures, and blockchain-enabled data security offer promising pathways to address existing challenges. These innovations could improve real-time analytics, safeguard patient privacy, and enable scalable AI/ML deployments across heterogeneous clinical environments.

4) Ethical, Regulatory, and Practical Considerations

a) ***Ethical Issues****:* Ethical considerations surrounding data privacy, transparency, and algorithmic fairness are paramount. As AI-driven decision systems gain autonomy, questions about data ownership, informed consent, and explainability become increasingly pressing. Bias in training datasets—especially those lacking demographic diversity—can exacerbate health disparities if left unaddressed. Ensuring algorithmic accountability and patient autonomy must be central to the design of such systems.

b) ***Regulatory Challenges****:* Regulatory frameworks have yet to catch up with the pace of technological innovation. There is an urgent need for regulatory bodies to develop standards that account for the dynamic and iterative nature of AI models, particularly regarding post-deployment monitoring, transparency in decision-making, and continuous performance validation.

c) ***Practical Implementation Barriers****:* In addition to ethical and regulatory hurdles, practical challenges such as device interoperability, high data throughput, cloud dependency, and cybersecurity risks limit large-scale implementation. Addressing these barriers requires a multi-pronged strategy, including developing standardized APIs, improving edge processing capabilities, and enforcing rigorous data security protocols.

5) Strengths and Limitations of the Review

a) ***Strengths****:* This review benefits from a comprehensive and systematic search strategy encompassing diverse sources and study designs. Our robust inclusion criteria and synthesis methods provide a nuanced and multidisciplinary perspective on the current state of AI/ML in wearable diabetes monitoring. The structured use of synthesis matrices enables clarity in pattern recognition and thematic mapping, enhancing the review's rigor and reproducibility.

b) ***Limitations****:* Notwithstanding its strengths, this review has certain limitations. The heterogeneity in study methodologies and reporting standards complicates meta-synthesis and limits generalizability. Publication bias, particularly the underreporting of negative findings, may skew the perceived efficacy of certain technologies. Additionally, language restrictions may have led to the exclusion of relevant non-English publications. Finally, given the rapid evolution of this field, some findings may become outdated as newer technologies emerge.

c) ***Recommendations for Future Reviews****:*

Future systematic reviews should adopt standardized data extraction templates and consider inclusion of grey literature, preprints, and non-English studies to provide a more comprehensive global perspective. Employing living review frameworks may also be beneficial to keep pace with rapid technological advancements in this domain.

IV. CONCLUSION

This section synthesizes the key findings from the study, looks at their wider effects on clinical practice, technology progress, policy creation, and upcoming research, and highlights the significant impact that AI/ML-integrated wearable devices can have in managing diabetes.

B. *Summary of Key Findings*

1) *Research Scope and Objectives:*

The primary aim of this study was to investigate the integration of Artificial Intelligence (AI) and Machine Learning (ML) technologies with wearable devices to enhance the monitoring and management of diabetes. By leveraging predictive modeling and real-time data analytics, the research aimed to improve the precision, efficiency, and responsiveness of diabetes care.

The study encompassed a comprehensive synthesis of diverse methodological approaches, including experimental studies, observational research, systematic reviews, and comparative benchmarking analyses. Experimental designs were notably utilized for developing and validating AI/ML models specifically tailored for continuous diabetes monitoring.

2) *Major Insights and Outcomes*

a) ***Enhanced Monitoring and Predictive Accuracy***: The incorporation of AI/ML algorithms significantly improved the accuracy of glucose level tracking and predictive analytics, offering clinicians precise insights to inform proactive care.

b) ***Improved Patient Outcomes***: The findings demonstrate that AI/ML-enhanced wearable devices contribute to early detection of diabetes-related complications and support personalized therapeutic adjustments, thereby improving patient outcomes.

c) ***Pivotal Role of Wearable Devices***: Wearables serve as crucial tools for continuous health data collection, enabling dynamic feedback loops that support real-time clinical decision-making and individualized care.

3) *Breadth of Research and Identified Gaps*

a) ***Interdisciplinary Nature****:* The research intersects multiple domains—bioengineering, clinical medicine, data science—highlighting the complexity and collaborative requirements of integrating AI/ML with health technologies.

b) ***Research Gaps****:* Key limitations include small sample sizes, a lack of long-term efficacy studies, and inadequate integration with existing healthcare infrastructure, all of which challenge generalizability and scalability.

c) ***Model Limitations****:* Challenges such as data privacy concerns, algorithmic transparency, and model bias remain significant. These issues must be addressed to ensure the clinical credibility and ethical deployment of AI-driven solutions.

C. *Implications for Clinical Practice, Technology, Policy, and Research*

1) *Clinical Practice*

a) ***Real-Time Monitoring for Early Intervention****:* Continuous data from wearables enables early detection of complications and supports timely, preventive interventions.

b) ***Personalized Treatment****:* Predictive analytics facilitate tailored care plans, enhancing therapeutic outcomes and promoting individualized patient management.

c) ***Telemedicine Integration****:* Wearables, when combined with telemedicine, extend healthcare delivery to remote and underserved populations, enhancing accessibility and continuity of care.

2) *Technological Innovation*

a) ***Sensor and Device Development****:* Continued innovation is required in developing non-invasive, high-accuracy sensors to improve patient compliance and data reliability.

b) ***Algorithmic Advancements****:* Refining AI/ML models to reduce false positives/negatives and improve predictive power is essential for clinical adoption.

c) ***Interoperability with EHRs****:* Seamless integration of wearable data with electronic health records (EHRs) will provide a unified view of patient health, enabling informed and holistic clinical decisions.

3) Policy-Making

a) ***Regulatory and Ethical Standards****:* There is a need for robust regulatory frameworks to ensure device reliability, data security, and ethical AI use in healthcare.

b) ***Funding and Investment****:* Strategic investments from public and private sectors are vital to support research, product development, and wide-scale implementation.

c) ***Patient Rights and Ethical Use****:* Ethical considerations surrounding consent, data ownership, and algorithmic accountability must be central to future policy formulations.

4) Future Research Directions

a) ***Interdisciplinary Collaboration****:* Cross-disciplinary efforts among clinicians, engineers, computer scientists, and policymakers are imperative for addressing the multifaceted challenges of this field.

b) ***Large-Scale and Longitudinal Studies****:* Empirical validation through comprehensive, long-term studies is necessary to substantiate the safety and efficacy of these technologies.

c) ***Incorporation of New Data Streams****:* Expanding data inputs to include environmental, behavioral, and lifestyle variables can further enhance model accuracy and personalization.

D. Final Reflections and Vision

1) Synthesis of Impact:This study highlights the transformative potential of integrating AI/ML with wearable devices for diabetes management. These technologies enable real-time decision support, promote personalized care strategies, and offer a scalable solution for proactive chronic disease management. The convergence of cutting-edge computational methods and healthcare delivery has the potential to revolutionize patient outcomes.

2) Call to Action:To realize the full potential of AI/ML in wearable health monitoring, sustained innovation, interdisciplinary collaboration, and strategic investment are essential. Bridging existing technological and systemic gaps requires coordinated efforts among all stakeholders.

3) Future Outlook*:* The outlook for AI/ML-driven wearables in healthcare is promising. As technologies mature and integration challenges are addressed, these systems are poised to empower patients in self-management and equip healthcare professionals with timely, data-driven insights. Ongoing research, ethical governance, and collaborative innovation will be pivotal in shaping a future of personalized, precise, and equitable diabetes care.

DECLARATION

Availability of data and materials : NA
Competing interests : NA
Funding: NA
Authors' contributions: NA
Acknowledgements: NA

REFERENCES

[1] InternationalDiabetesFederation,“IDFDiabetesAtlas,10thEdition,”2021. Accessed: 2021-XX-XX. [Online]. Available:https://www.diabetesatlas.org/
[2] World Health Organization, “Global Report on Diabetes,” 2020.Accessed: 2020-XX-XX. [Online]. Available:https://www.who.int/publications/i/item/9789241565257
[3] American Diabetes Association, “Standards of Medical Care inDiabetes—

2022,"DiabetesCare,vol.45,Suppl.1,pp.S1–S264,2022,doi:10.2337/dc22-S001
[4] P. Zimmet, K. G. M. M. Alberti, D. J. Magliano, and P. H. Bennett,"Diabetes: A 21st Century Challenge," The Lancet Diabetes &Endocrinology,vol.4,no.11,pp.850–860,2016,doi:10.1016/S2213-8587(16)30219-8
[5] L. Heinemann, "Continuous Glucose Monitoring: A Review of theCurrent Technologies," Journal of Diabetes Science and Technology,vol. 12, no. 4, pp. 843–850, 2018, doi: 10.1177/1932296818756609
[6] S. Patel, H. Park, P. Bonato, L. Chan, and M. Rodgers, "A Review ofWearable Sensors and Systems with Application in Rehabilitation,"Journal of NeuroEngineering and Rehabilitation, vol. 9, no. 1, p. 21,2012, doi: 10.1186/1743-0003-9-21
[7] I. Contreras and J. Vehi, "Artificial Intelligence for DiabetesManagement and Decision Support: Literature Review," Journal ofDiabetesScienceandTechnology,vol.12,no.5,pp.1015–1023,2018,doi:10.1177/1932296818776612
[8] A.Esteva,A.Robicquet,B.Ramsundar,V.Kuleshov,M.DePristo,K.Chou, C. Cui, G. Corrado, S. Thrun, and J. Dean, "A Guide to DeepLearning in Healthcare," Nature Medicine, vol. 25, pp. 24–29, 2019,doi:10.1038/s41591-018-0316-z
[9] M.Bashir,A.Ahmad,F.Qamar,etal.,"ChallengesandOpportunitiesin AI-Enabled Wearable Devices for Diabetes Management," JournalofMedicalSystems,vol.44,no.7,p.125,2020,doi:10.1007/s10916-020-01575-6
[10] M. Swan, "Health 2050: The Realization of Personalized MedicineThrough Crowdsourcing, the Quantified Self, and the ParticipatoryBiocitizen," Journal of Personalized Medicine, vol. 2, no. 3, pp. 93–118, 2012, doi: 10.3390/jpm2030093
[11] I.Kavakiotis,O.Tsave,A.Salifoglou,N.Maglaveras,I.Vlahavas,and I. Chouvarda, "Machine Learning and Data Mining Methods inDiabetes Research," Computational and Structural BiotechnologyJournal, vol. 15, pp. 104–116, 2017, doi: 10.1016/j.csbj.2016.12.005
[12] H. Arksey and L. O'Malley, "Scoping Studies: Towards aMethodologicalFramework,"InternationalJournalofSocialResearchMethodology, vol. 8, no. 1, pp. 19–32, 2005, doi:10.1080/1364557032000119616
[13] R. M. Bergenstal, R. W. Beck, K. L. Close, et al., "GlucoseManagementIndicator(GMI): ANewTermforEstimatingA1CfromContinuous Glucose Monitoring," Diabetes Care, vol. 41, no. 11, pp.2275–2280, 2018, doi: 10.2337/dc18-0791
[14] X.Li,J.Dunn,D.Salins,G.Zhou,W.Zhou,S.M.Schüssler-FiorenzaRose,andP.Arolla,"DigitalHealth:TrackingPhysiomesandActivityUsing Wearable Biosensors Reveals Useful Health-RelatedInformation," PLoS Biology, vol. 15, no. 1, e2001402, 2020, doi:10.1371/journal.pbio.2001402
[15] U.S.FoodandDrugAdministration,"ArtificialIntelligenceandMachineLearninginSoftwareasaMedicalDevice,"2021.Accessed:2021-XX-XX.[Online].Available:https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-and-machine-learning-software-medical-device
[16] J. Daniels, P.Herrero, and P. Georgiou, "A Multitask LearningApproachtoPersonalizedBloodGlucosePrediction,"IEEEJournalofBiomedical and Health Informatics, n.d. [Online].
[17] H.Ali, D.White, S.Madanian, B.K. Russel, N.Malik, and I. Khan,"Prediction of Interstitial Glucose Levels through Wearable Sensorsusing Machine Learning," 2023. [Online].
[18] "Internetof Things Based on Electronic and Mobile Health Systemsfor Blood Glucose Continuous Monitoring and Management," IEEEJournals & Magazine. [Online].
[19] J.XieandQ.Wang,"BenchmarkingMachineLearningAlgorithmsonBlood Glucose Prediction for Type I Diabetes in Comparison WithClassical Time-Series Models," IEEE Transactions on

BiomedicalEngineering, vol. 67, no. 11, pp. 3101–3124, 2020.
[20] M.M.Arslan,X. Yang,Z.Zhang,S.U.Rahma,andM. Ullah,"Advancing Healthcare Monitoring: Integrating Machine LearningWith Innovative Wearable and Wireless Systems for ComprehensivePatient Care," IEEE Sensors Journal, n.d. [Online].
[21] J.Daniels, P.Herrero, and P.Georgiou, "A Multitask LearningApproach to Personalized Blood Glucose Prediction," [Online].Available:(link)
[22] K.Deepak,K. Jain,S.Srinivas,N. Venkata,R.Srinivasu,Manikandan, S.Venkata, N.Srinivasu, Jain, and R.Manikandan,"Machine Learning-Based Monitoring System With IoT UsingWearable Sensors and Pre-Convoluted Fast Recurrent NeuralNetworks (P-FRNN)," [Online]. Available: (link)
[23] G.Zha, Z. Mei, Y.Zhang, X.Ma, B.Lo, D. Chen, and G. Zhang, "ANoninvasiveBloodGlucoseMonitoringSystemBasedonSmartphonePPGSignalProcessingandMachineLearning,"IEEETransactionsonIndustrial Informatics, [Online].
[24] K. Li, J.Daniels, C.Liu, P.Herrero, and P.Georgiou, "ConvolutionalRecurrent Neural Networks for Glucose Prediction," [Online].
[25] A. Site, J.Nurmi, and E. S. Lohan, "Machine-Learning-BasedDiabetes Prediction Using Multisensor Data," IEEE Sensors Journal,[Online].
[26] T.Zhu,I.Afentakis,K. Li,R.Armiger,N. Hill,N.Oliver,and P.Georgiou, "Multi-Horizon Glucose Prediction Across Populationswith Deep Domain Generalization," IEEE Journal of Biomedical andHealth Informatics, [Online].
[27] T.Vaiyapur,G. Alhar,S.M.Dharmaraj,Y.Bouteraa,S.Misr, J.Venkata, N.Ramesh, and S.N. Mohanty, "IoT-Enabled EarlyDetection of Diabetes Diseases Using Deep Learning andDimensionality Reduction Techniques," IEEE Access, [Online].
[28] S. Langarica,D. DeLaVega,N. Cariman,M.Miranda,D. C.Andrade, F.Núñez, and M.Rodriguez-Fernandez, "Deep Learning-Based Glucose Prediction Models: A Guide for Practitioners and aCurated Dataset for Improved Diabetes Management," IEEE OpenJournal of Engineering in Medicine and Biology, [Online].
[29] "IoMT-Enabled Real-Time Blood Glucose Prediction With DeepLearningandEdgeComputing,"IEEEJournals&Magazine,[Online].
[30] H. H. Hwong, S. Sivakumar, and K. H. Lim, "Machine Learning-Based Glucose Monitoring Techniques for Diabetes Management: AReview," [Online].
[31] E.Venitha, V.Vijayashanthi, M.Parameswari, and S. D. Hariharan,"Real-time Non-invasive Blood Glucose Monitoring using AdvancedMachine Learning Techniques," 2023. [Online].
[32] A.Aliber,I.Pupillo,S.Terna,E.Macii,S.DiCataldo,A.Acquaviva,and A.Aliberti, "A Multi-Patient Data-Driven Approach to BloodGlucose Prediction," [Online].
[33] S.A. Siddiqui, Y.Zha, H.Song, Z.Obradovic, and Y.Zhang, "Pain-Free Blood Glucose Monitoring Using Wearable Sensors: RecentAdvancements and Future Prospects," [Online].
[34] Y. Yu, J.Huang, J.Zhu, and S.Liang, "An Accurate NoninvasiveBlood Glucose Measurement System Using Portable Near-InfraredSpectrometer and Transfer Learning Framework," [Online].
[35] K. Du, J. Li, Z.Huang, H.Song, Y.Zhang, and Z. Mei, "A non-invasivebloodglucosedetectionsystembasedonphotoplethysmogramwith multiplenear-infrared sensors," IEEE Journal of Biomedical andHealth Informatics, [Online].
[36] S.Zanelli, M. A. El Yacoubi, and M. Ammi, "Type 2 DiabetesDetection With Light CNN From Single Raw PPG Wave," IEEEAccess, [Online].
[37] A. Mubashir, J.Li, B.Fan, and Z.Nie, "PPG based NoninvasiveBlood Glucose Monitoring using Multi-view Attention and CascadedBiLSTM Hierarchical Feature Fusion Approach," IEEE Journal ofBiomedical and Health Informatics, 2024. [Online].

[38] A.Hina and W.Saadeh, “A 186µW Photoplethysmography-BasedNoninvasive Glucose Sensing SoC,” IEEE Sensors Journal, [Online].
[39] Y.Yang, J.Chen, J.Wei, Z.Wang, J.Song, Y.Zhang, and J.Zhao,“Noninvasive Blood Glucose Detection System With Infrared PulseSensor and Hybrid Feature Neural Network,” IEEE Sensors Journal,[Online].
[40] Y.Obeidat and A.Ammar, “ASystem for Blood Glucose Monitoringand Smart Insulin Prediction,” IEEE Sensors Journal, [Online].
[41] M. Shokrekhodaei, D.P. Cistola, R.C. Roberts, and S. Quinones,“Non-InvasiveGlucoseMonitoringUsingOpticalSensorandMachineLearning Techniques for Diabetes Applications,” IEEE Access,[Online].
[42] R.Marzouk, A.S. Alluhaidan, S.El_Rahman, and A.S. Alluhaidan,“AnAnalyticalPredictiveModelsandSecureWeb-BasedPersonalizedDiabetes Monitoring System,” IEEE Access, [Online]. Available:(link)
[43] F.Tena,O.Garnica,J.Lanchares,D.Ávila,andJ.Hidalgo,“AnLSTM-based Neural Network Wearable System for Blood GlucosePrediction in People with Diabetes,” [Online].
[44] M.Saleh,A.L.Resha,S.Amin,M.A.Zeb,A.Sulaiman, H.Alshahrani,andM.A.Elmagzoub,“AnInnovativeEnsembleDeepLearning Clinical Decision Support System for Diabetes Prediction,”IEEE Access, [Online].
[45] N.Kazemi,M.Abdolrazzaghi,P.E.Light,andP.Musilek,“In-humantesting of a non-invasive continuous low-energy microwave glucosesensor with advanced machine learning capabilities,” Biosensors andBioelectronics, vol. 115668, Sep. 2023. [Online].
[46] V.P. Rachim and W.-Y. Chung, “Wearable-band type visible-nearinfraredopticalbiosensorfornon-invasivebloodglucosemonitoring,”2019.[Online].
[47] Y.Zou,Z.Chu,J.Guo,S.Liu,X.Ma,andJ. Guo,“Minimallyinvasive electrochemical continuous glucose monitoring sensors:Recentprogress andperspective,”Biosensors andBioelectronics, vol.115103, Jan. 2023. [Online].
[48] M.Lim, W.Lee, B.Jeon, and S.Kim, “A Blood Glucose ControlFramework Based on Reinforcement Learning With Safety andInterpretability In Silico Validation,” n.d. [Online].
[49] R.Marzouk, A.S. Alluhaidan, S.ElRahman, and A. Alluhaidan, “AnAnalytical Predictive Models and Secure Web-Based PersonalizedDiabetes Monitoring System,” n.d. [Online].
[50] H.Siddiqui et al., “A Survey on Machine and Deep Learning Modelsfor Childhood and Adolescent Obesity,” n.d. [Online]. Available: (link)
[51] M.Saleh et al., “An Innovative Ensemble Deep Learning ClinicalDecision Support System for Diabetes Prediction,” n.d. [Online].
[52] P.Nuankaew,S.Chaising, andP.Temdee,“AverageWeightedObjectiveDistance-BasedMethodforType2DiabetesPrediction,” n.d.[Online].
[53] A.Farrukh,M.Al-Rakhami,A.Derhab,andA.C.Bukhari,“Detectionand Prediction of Diabetes Using Data Mining: A ComprehensiveReview,” n.d. [Online].
[54] A.S.Abdullah,V.Naga,P.Shashank,D. Altrin,andL.Hudson,“Disseminating the Risk Factors With Enhancement in PrecisionMedicine Using Comparative Machine Learning Models forHealthcare Data,” n.d. [Online].
[55] R.Kapur et al., “GlucoBreath: An IoT, ML and Breath-Based Non-Invasive Glucose Meter,” n.d. [Online].
[56] M.Shokrekhoda,D.Cistola,R.Roberts,S.Quinones,and

M.Shokrekhodaei, “Non-Invasive Glucose Monitoring Using OpticalSensorandMachineLearningTechniquesforDiabetesApplications,” n.d.[Online].

[57] L.-Y.Zhang et al., “Prediction of Dynamic Plantar Pressure FromInsole Intervention for Diabetic Patients Based on Patch-BasedMultilayer Perceptron With Localization Embedding,” n.d. [Online].

[58] V.Daliya, T.Rames, and S.-B. Ko, “An Optimised MultivariableRegression Model for Predictive Analysis of Diabetic DiseaseProgression,” n.d. [Online].

[59] R.Ferdousi, M.A. Hossain, and A.E. Saddik, “SPECIAL SECTIONON AI AND IOT CONVERGENCE FOR SMART HEALTH,” n.d. [Online].

[60] N.Fazakis,“MachineLearningToolsforLong-TermType2DiabetesRisk Prediction,” n.d. [Online].

[61] L.Jia,Z. Wang,S. Lv,andZ.Xu,“PE_DIM:AnEfficientProbabilisticEnsembleClassificationAlgorithmforDiabetesHandlingClass Imbalance and Missing Values,” n.d. [Online].

[62] N.Nor et al., “PredictionModels forType 2 Diabetes Progression: ASystematic Review,” n.d. [Online].

[63] N.Shuzanetal.,“QU-GM:AnIoTBasedGlucoseMonitoringSystemFrom Photoplethysmography, Blood Pressure and Demographic DataUsing Machine Learning,” n.d. [Online].

[64] M. Zubair,M.Shamim,H. Hussein,andM. Shiblee,“DIAGNO~1.PDF,” n.d. [Online].

[65] E.Pustozerov et al., “Development and Evaluation of a MobilePersonalized Blood Glucose Prediction System for Patients WithGestational Diabetes Mellitus,” n.d. [Online].

[66] I.Rodríguez-Rodríguez,M.Campo-Valera,J.-V.Rodríguez,and W.Woo, “IoMT Innovations in Diabetes Management: PredictiveModels Using Wearable Data,” n.d. [Online].

[67] A.Woldaregay et al., “Data-Driven Blood Glucose PatternClassification and Anomalies Detection: Machine-LearningApplications in Type 1 Diabetes,” n.d. [Online].

[68] N.Katiyar, H.Thakur, and A.Ghatak, “Recent Advancements UsingMachine Learning and Deep Learning Approaches for DiabetesDetection: A Systematic Review,” n.d. [Online].

[69] M. Danieli et al., “Machine Learning Application in AutoimmuneDiseases: State of Art and Future Prospectives,” n.d. [Online].

[70] W.Costa, E.Pereira, and G.Kontonatsios, “Use of Smartphones forHypoglycaemia Prediction - A Feasibility Study,” n.d. [Online].

[71] J.Hanna et al., “Wearable Flexible Body-Matched ElectromagneticSensors for Personalized Non-Invasive Glucose Monitoring,” n.d.[Online].

[72] E.Daboss, M.Komkova, V.Nikitina, E.Andreev, D.Vokhmyanina,and A.Karyakin, “Noninvasive Monitoring of Glycemia Level inDiabetic Patients by Wearable Advanced Biosensors,” n.d. [Online].

[73] H.Liu, W. Liu, C.Sun, W.Huang, and X.Cui, “A Review of Non-Invasive Blood Glucose Monitoring Through Breath Acetone andBody Surface,” n.d. [Online].

[74] A.Martinsetal.,“AComprehensiveReviewofNon-InvasiveOpticaland Microwave Biosensors for Glucose Monitoring,” n.d. [Online].

[75] X.Peng, Y.-X. Yan,andH. Liu,“OntheUseof Fiber Lasers in Non-Invasive Blood Glucose Monitoring,” n.d. [Online].

[76] J. Li et al., “Establishment of Noninvasive Diabetes Risk PredictionModelBasedonTongueFeaturesandMachineLearningTechniques,” n.d.[Online].

[77] N. Juntree et al., "Unveiling Role of Carbon Dots for Non-Invasiveand Ultra-Sensitive Glucose Detection in Biofluids for PersonalPreventive Care Testing," n.d. [Online].
[78] B. Shi et al., "Assessing Elevated Blood Glucose Levels ThroughBlood Glucose Evaluation and Monitoring Using Machine Learningand Wearable Photoplethysmography Sensors: AlgorithmDevelopment and Validation," n.d. [Online].
[79] H.Kim,D.Jung,H.Choi,T.Hong,andA.T.I.C.L.E.I.N.F.O, "Advanced Prediction Model for Individual Thermal ComfortConsidering Blood Glucose and Salivary Cortisol," n.d. [Online].
[80] H.Liu, W. Liu, C.Sun, W.Huang, and X.Cui, "A Review of Non-Invasive Blood Glucose Monitoring Through Breath Acetone andBody Surface," n.d. [Online].
[81] F. Sunstrum, J.Khan, N.-W. Li, and A.Welsh, "Wearable TextileSensors for Continuous Glucose Monitoring," n.d. [Online].
[82] Q.Chen, Y.Zhao, and Y. Liu, "Chinese Chemical Letters," n.d.[Online].
[83] Fakhar, M.H., Baig, M.Z., Ali, A., Rana, M.T.A., Khan, H., Afzal, W., Farooq, H.U. and Albouq, S. 2024. A Deep Learning-based Architecture for Diabetes Detection, Prediction, and Classification. Engineering, Technology & Applied Science Research. 14, 5 (Oct. 2024), 17501–17506. DOI:https://doi.org/10.48084/etasr.8354.
[84] A.Prabha, J.Yadav, A.Rani,and V.Singh, "Intelligent Estimation ofBlood Glucose Level Using Wristband PPG Signal and PhysiologicalParameters," n.d. [Online].
[85] A. Ahmed,S. Aziz,U.Qidwai,A. Abd-Alrazaq,andJ.Sheikh,"Performance of Artificial Intelligence Models in Estimating BloodGlucoseLevelAmongDiabeticPatientsUsingNon-InvasiveWearableDevice Data," n.d. [Online].
[86] E.Daskalaki et al., "The Potential of Current Noninvasive WearableTechnology for the Monitoring of Physiological Signals in theManagement of Type 1 Diabetes: Literature Survey," n.d. [Online].
[87] N.Kazanskiy, S.Khonina, and M.Butt, "A Review on FlexibleWearables–RecentDevelopmentsinNon-InvasiveContinuousHealthMonitoring," n.d. [Online].
[88] Y.Zou,Z.Chu,J.Guo,S.Liu,X.Ma,andJ. Guo,"MinimallyInvasive Electrochemical Continuous Glucose Monitoring Sensors:Recent Progress and Perspective," n.d. [Online].
[89] W. Li et al., "Non-lab and Semi-lab Algorithms for ScreeningUndiagnosed Diabetes: A Cross-Sectional Study," n.d. [Online].
[90] S.Health et al., "Personalized Diabetes Monitoring PlatformLeveragingIoMTandAIforNon-InvasiveEstimation,"n.d.[Online].
[91] Health,B.Ahmed,M.Ali,M.Masud,andM.Naznin,"RecentTrendsand Techniques of Blood Glucose Level Prediction for DiabetesControl," n.d. [Online].
[92] M.Sharma, P. Kumar, and C. Puri, "A Comparative Analysis ofDiabetesPrediction SystemUsingRegressorMethods,"n.d.[Online].
[93] X. Zou et al., "Differential Effect of Interventions in Patients withPrediabetes Stratified by a Machine Learning-Based DiabetesProgression Prediction Model," n.d. [Online].
[94] J. D.Onwuchekwa,D.Claus,C.Weber,andM.Maleshkova,"EnhancedPredictiveMonitoringofHypoglycemiainType1DiabetesUsing Shapelet-Based Analysis of Wearable Sensor Data," n.d.[Online].
[95] K.Janapati, A.Bajjuri, Y.S. Vemula, and V.Chindam, "IoT-basedContinuous Glucose Monitoring System," n.d. [Online].
[96] S.Saha,S.Fattah,U. Saha,andS. Saha,"PPG-BasedFeatureExtraction for Type II Diabetes Prediction: A Machine LearningApproach," n.d. [Online].
[97] M.Wang,Z.Lin,R.Li,Y.Li,andJ.Su,"PredictingDiseaseProgresswith Imprecise Lab Test Results," n.d.

[Online].
[98] D.Kaviyaadharshani et al., "Diagnosing Diabetes using MachineLearning-based Predictive Models," n.d. [Online].
[99] D.Tatli,V.Papapanagiotou,A.Liakos,A.Tsapas,andA.Delopoulos,"Prediabetes Detection in Unconstrained Conditions Using WearableSensors," n.d. [Online].
[100]H. Kulkarni et al., "Machine-Learning Algorithm to NoninvasivelyDetect Diabetes and Prediabetes from Electrocardiogram," n.d.[Online].
[101]F. Oliveira et al., "MACHINE LEARNING-BASED DIABETES DETECTION USING PHOTOPLETHYS MOGRAPHY SIGNALFEATURES: APreprint,"n.d.[Online].
[102]J.Wu,Y.Liu,H.Yin,andM.Guo,"ANewGenerationofSensorsforNon-Invasive Blood Glucose Monitoring," n.d. [Online].
[103]H. Gunathilaka et al., "Non-Invasive Diagnostic Approach forDiabetes Using Pulse Wave Analysis and Deep Learning," n.d.[Online].